0 CHECKOUT

Esophageal Cancer - Pipeline Review, H2 2015

  • ID: 3500424
  • October 2015
  • 355 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Adaptimmune Limited
  • Array BioPharma Inc.
  • Celgene Corporation
  • ImmunoFrontier, Inc.
  • Mebiopharm Co., Ltd.
  • Pfizer Inc.
  • MORE

Esophageal Cancer - Pipeline Review, H2 2015

Summary

The report ‘Esophageal Cancer - Pipeline Review, H2 2015’, provides an overview of the Esophageal Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Adaptimmune Limited
  • Array BioPharma Inc.
  • Celgene Corporation
  • ImmunoFrontier, Inc.
  • Mebiopharm Co., Ltd.
  • Pfizer Inc.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Esophageal Cancer Overview

Therapeutics Development

Pipeline Products for Esophageal Cancer - Overview

Pipeline Products for Esophageal Cancer - Comparative Analysis

Esophageal Cancer - Therapeutics under Development by Companies

Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes

Esophageal Cancer - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Esophageal Cancer - Products under Development by Companies

Esophageal Cancer - Products under Investigation by Universities/Institutes

Esophageal Cancer - Companies Involved in Therapeutics Development

Adaptimmune Limited

Advantagene, Inc.

Advaxis, Inc.

Amgen Inc.

ArQule, Inc.

Array BioPharma Inc.

Aslan Pharmaceuticals Pte. Ltd.

AstraZeneca Plc

ATLAB Pharma SAS

AVEO Pharmaceuticals, Inc.

Bayer AG

Boehringer Ingelheim GmbH

Celgene Corporation

Celldex Therapeutics, Inc.

Cellectar Biosciences, Inc.

Cerulean Pharma, Inc.

Cyclacel Pharmaceuticals, Inc.

Daiichi Sankyo Company, Limited

Genmab A/S

Glycotope GmbH

Hutchison MediPharma Limited

Ignyta, Inc.

ImmunoFrontier, Inc.

ImmunoGen, Inc.

Immunomedics, Inc.

Johnson & Johnson

Karyopharm Therapeutics, Inc.

MacroGenics, Inc.

Mebiopharm Co., Ltd.

MedImmune, LLC

Novartis AG

Omeros Corporation

Omnitura Therapeutics Inc.

Oncolys BioPharma Inc.

Ono Pharmaceutical Co., Ltd.

Pfizer Inc.

Precision Biologics, Inc.

Proteo, Inc.

Puma Biotechnology, Inc.

Shionogi & Co., Ltd.

Spectrum Pharmaceuticals, Inc.

Symphogen A/S

Synta Pharmaceuticals Corp.

Transgene Biotek Limited

VioQuest Pharmaceuticals, Inc.

Virocan Therapeutics Private Limited

Zhejiang BetaPharma Co., Ltd.

Esophageal Cancer - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

1-BB1 - Drug Profile

ADXS-HER2 - Drug Profile

afatinib dimaleate - Drug Profile

alpelisib - Drug Profile

AMG-337 - Drug Profile

ATL-101 - Drug Profile

binimetinib - Drug Profile

CDX-1401 - Drug Profile

Cell Therapy 1 for Oncology - Drug Profile

Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile

Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile

cetuximab biobetter - Drug Profile

CRLX-101 - Drug Profile

CYC-140 - Drug Profile

dacomitinib - Drug Profile

DKN-01 - Drug Profile

durvalumab - Drug Profile

elgemtumab - Drug Profile

ficlatuzumab - Drug Profile

futuximab - Drug Profile

ganetespib - Drug Profile

gedatolisib - Drug Profile

gefitinib - Drug Profile

Gene Therapy for Esophageal Cancer - Drug Profile

Gene Therapy to Activate p53 for Oncology - Drug Profile

HMPL-309 - Drug Profile

HuMax-TF-ADC - Drug Profile

I131-CLR1404 - Drug Profile

icotinib hydrochloride - Drug Profile

IMF-001 - Drug Profile

IMGN-289 - Drug Profile

JNJ-42756493 - Drug Profile

margetuximab - Drug Profile

MBP-426 - Drug Profile

MMD-37K - Drug Profile

MVXONCO-1 - Drug Profile

NEO-201 - Drug Profile

neratinib - Drug Profile

nimotuzumab - Drug Profile

nintedanib - Drug Profile

nivolumab - Drug Profile

OBP-301 - Drug Profile

OMN-54 - Drug Profile

paclitaxel albumin bound - Drug Profile

panitumumab - Drug Profile

pasireotide LAR - Drug Profile

patritumab - Drug Profile

PCA-062 - Drug Profile

pralatrexate - Drug Profile

PTVICN-001 - Drug Profile

rAAV-VICN003 - Drug Profile

RXDX-106 - Drug Profile

S-588410 - Drug Profile

sacituzumab govitecan - Drug Profile

selinexor - Drug Profile

Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Drug Profile

Small Molecule to Target LGR5 for Esophageal Adenocarcinoma - Drug Profile

Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer - Drug Profile

SMYD-2BAY02 - Drug Profile

TBL-0805E - Drug Profile

tiprelestat - Drug Profile

tivantinib - Drug Profile

triciribine phosphate - Drug Profile

Vaccine for Esophageal Cancer - Drug Profile

Vaccine for Esophageal Cancer and Colorectal Cancer - Drug Profile

varlitinib - Drug Profile

Esophageal Cancer - Recent Pipeline Updates

Esophageal Cancer - Dormant Projects

Esophageal Cancer - Discontinued Products

Esophageal Cancer - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Esophageal Cancer, H2 2015

Number of Products under Development for Esophageal Cancer - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Development by Companies, H2 2015 (Contd..1)

Number of Products under Development by Companies, H2 2015 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Development by Companies, H2 2015 (Contd..2)

Products under Development by Companies, H2 2015 (Contd..3)

Products under Investigation by Universities/Institutes, H2 2015

Esophageal Cancer - Pipeline by Adaptimmune Limited, H2 2015

Esophageal Cancer - Pipeline by Advantagene, Inc., H2 2015

Esophageal Cancer - Pipeline by Advaxis, Inc., H2 2015

Esophageal Cancer - Pipeline by Amgen Inc., H2 2015

Esophageal Cancer - Pipeline by ArQule, Inc., H2 2015

Esophageal Cancer - Pipeline by Array BioPharma Inc., H2 2015

Esophageal Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2015

Esophageal Cancer - Pipeline by AstraZeneca Plc, H2 2015

Esophageal Cancer - Pipeline by ATLAB Pharma SAS, H2 2015

Esophageal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015

Esophageal Cancer - Pipeline by Bayer AG, H2 2015

Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015

Esophageal Cancer - Pipeline by Celgene Corporation, H2 2015

Esophageal Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015

Esophageal Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2015

Esophageal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2015

Esophageal Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015

Esophageal Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2015

Esophageal Cancer - Pipeline by Genmab A/S, H2 2015

Esophageal Cancer - Pipeline by Glycotope GmbH, H2 2015

Esophageal Cancer - Pipeline by Hutchison MediPharma Limited, H2 2015

Esophageal Cancer - Pipeline by Ignyta, Inc., H2 2015

Esophageal Cancer - Pipeline by ImmunoFrontier, Inc., H2 2015

Esophageal Cancer - Pipeline by ImmunoGen, Inc., H2 2015

Esophageal Cancer - Pipeline by Immunomedics, Inc., H2 2015

Esophageal Cancer - Pipeline by Johnson & Johnson, H2 2015

Esophageal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015

Esophageal Cancer - Pipeline by MacroGenics, Inc., H2 2015

Esophageal Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2015

Esophageal Cancer - Pipeline by MedImmune, LLC, H2 2015

Esophageal Cancer - Pipeline by Novartis AG, H2 2015

Esophageal Cancer - Pipeline by Omeros Corporation, H2 2015

Esophageal Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2015

Esophageal Cancer - Pipeline by Oncolys BioPharma Inc., H2 2015

Esophageal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015

Esophageal Cancer - Pipeline by Pfizer Inc., H2 2015

Esophageal Cancer - Pipeline by Precision Biologics, Inc., H2 2015

Esophageal Cancer - Pipeline by Proteo, Inc., H2 2015

Esophageal Cancer - Pipeline by Puma Biotechnology, Inc., H2 2015

Esophageal Cancer - Pipeline by Shionogi & Co., Ltd., H2 2015

Esophageal Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015

Esophageal Cancer - Pipeline by Symphogen A/S, H2 2015

Esophageal Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015

Esophageal Cancer - Pipeline by Transgene Biotek Limited, H2 2015

Esophageal Cancer - Pipeline by VioQuest Pharmaceuticals, Inc., H2 2015

Esophageal Cancer - Pipeline by Virocan Therapeutics Private Limited, H2 2015

Esophageal Cancer - Pipeline by Zhejiang BetaPharma Co., Ltd., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Esophageal Cancer Therapeutics - Recent Pipeline Updates, H2 2015

Esophageal Cancer - Dormant Projects, H2 2015

Esophageal Cancer - Dormant Projects (Contd..1), H2 2015

Esophageal Cancer - Dormant Projects (Contd..2), H2 2015

Esophageal Cancer - Dormant Projects (Contd..3), H2 2015

Esophageal Cancer - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Esophageal Cancer, H2 2015

Number of Products under Development for Esophageal Cancer - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Adaptimmune Limited
Advantagene, Inc.
Advaxis, Inc.
Amgen Inc.
ArQule, Inc.
Array BioPharma Inc.
Aslan Pharmaceuticals Pte. Ltd.
AstraZeneca Plc
ATLAB Pharma SAS
AVEO Pharmaceuticals, Inc.
Bayer AG
Boehringer Ingelheim GmbH
Celgene Corporation
Celldex Therapeutics, Inc.
Cellectar Biosciences, Inc.
Cerulean Pharma, Inc.
Cyclacel Pharmaceuticals, Inc.
Daiichi Sankyo Company, Limited
Genmab A/S
Glycotope GmbH
Hutchison MediPharma Limited
Ignyta, Inc.
ImmunoFrontier, Inc.
ImmunoGen, Inc.
Immunomedics, Inc.
Johnson & Johnson
Karyopharm Therapeutics, Inc.
MacroGenics, Inc.
Mebiopharm Co., Ltd.
MedImmune, LLC
Novartis AG
Omeros Corporation
Omnitura Therapeutics Inc.
Oncolys BioPharma Inc.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Precision Biologics, Inc.
Proteo, Inc.
Puma Biotechnology, Inc.
Shionogi & Co., Ltd.
Spectrum Pharmaceuticals, Inc.
Symphogen A/S
Synta Pharmaceuticals Corp.
Transgene Biotek Limited
VioQuest Pharmaceuticals, Inc.
Virocan Therapeutics Private Limited
Zhejiang BetaPharma Co., Ltd.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Photocure ASA
  • Roche Diagnostics Ltd.
  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Becton, Dickinson and Company (BD)